?What
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOOD TO SEE YOUR STILL HERE B.J. THIS TICKER IS GOING TO CHANGE THE WORLD OF MEDICENE FOREVER. STILL BUYING AT THESE RIDICULOUS PRICES
ENZC
This is starting to look a little like Game Stop. INND
and yes I'm holding many millions and will not sell my shares, today anyway LOL
MY BATTLE CRY
REMEMBER THIS DAY BOYS BECAUSE IT WILL BE REMEMBERED FOR ALL TIME
Can this baby be called a life changer?
ENZC
Yeah well it's about time people woke up to what is going to happen here. ENZC
I totoly agree/ Theres a lot of room for other pharma's. I'm still thinking that the ceo could be nominated for a Nobel prize. ENZO
Millions of lives will be saved. ENZC
jUST LOVING BEING LONGGGGGGGGGGGGGGGGG HERE AT ENZC
RENNOVA COMPLETES AGREEMENT TO SEPARATE ITS SOFTWARE AND GENETIC DIAGNOSTICS INTERPRETATION DIVISIONS INTO INNOVAQOR, INC. (OTC: INOQ) [UPDATED] -- originally dated Jan 6, 2021
2:39 PM ET 1/15/21 | GlobeNewswire
Editor's Note: This item was released by Globe Newswire on January 6th, but wasn't published at that time due to technical issues.
RENNOVA COMPLETES AGREEMENT TO SEPARATE ITS SOFTWARE AND GENETIC DIAGNOSTICS INTERPRETATION DIVISIONS INTO INNOVAQOR, INC. (OTC: INOQ) [UPDATED]
WEST PALM BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW) ("Rennova" or the "Company"), an owner and operator of rural hospitals in Tennessee, announces that on December 31. 2020, it completed an agreement with InnovaQor, Inc. (OTC: INOQ) (InnovaQor) a CO based public company, to merge its software and genetic testing interpretation divisions, Health Technology Solutions, Inc. (HTS) and Advanced Molecular Services Group, Inc., (AMSG) and their subsidiaries into InnovaQor. After closing these entities will operate as wholly owned subsidiaries of InnovaQor. Closing is subject to a number of customary conditions for a transaction of this nature and is intended to happen on or before January 31. 2021.
InnovaQor has previously completed a license agreement giving it certain rights to assets and technology from TPT Global Tech, Inc's. (OTC: TPTW) proprietary live streaming communication technology. As part of the License agreement InnovaQor and TPT have agreed a development project to create a next generation telehealth type platform. It is intended to combine the TPT and Rennova assets and technology into a smart phone and computer accessible healthcare platform to facilitate a patient's immediate access to healthcare and their local hospital or doctors office, for initial consultation, scheduling of appointments and follow on care and other added value services that may be one off or recurring.
InnovaQor has agreed to complete the necessary steps and SEC filings with the intent to facilitate TPT shareholders receiving approximately 2,500,000 shares in InnovaQor, and Rennova Health, Inc. shareholders receiving approximately $5M of Preference shares which will be converted to common shares. As described in the agreement TPT will retain direct ownership of a further 2,500,000 shares and Rennova will retain ownership of an additional $17.5M of Preference shares with certain conversion rights and restrictions, in InnovaQor. An additional 1,000,000 shares in InnovaQor will be allocated to TPT or its' assignees as an incentive to assist in product development.
"Rennova has previously disclosed its intention to separate its technology and software divisions. This agreement with InnovaQor finalizes these plans and the technology being contributed to the project by TPT creates an exciting opportunity to revolutionize the way patients access healthcare and continued aftercare", said Seamus Lagan, CEO of Rennova Health "We see first-hand the need our rural hospitals have to secure and retain patients. The product envisaged here will create immense value for many health care providers and provide a permanent solution to the current and probably extended reluctance of many people in the current pandemic to visit doctors' practices and hospitals for initial consultations. A phone based product that reduces a delay in access to healthcare and better manages ongoing care will save lives"
About Rennova Health, Inc.
Rennova operates three rural hospitals and a physician's office in Tennessee and a physician's office in Kentucky and provides industry-leading diagnostics and supportive software solutions to healthcare providers. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Contacts:
Rennova Health
Sebastien Sainsbury, 561-666-9818
ssainsbury@rennovahealth.com
# # #
> Dow Jones Newswires
January 15, 2021 14:39 ET (19:39 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
Unless stated otherwise, the web content provided by the E*TRADE family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by E*TRADE Securities LLC or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by E*TRADE Securities LLC or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.
E*TRADE may make available links to other, third party sites or electronic services providers. The material is also being provided to you for educational purposes only unless stated otherwise. The content has been written by a third party not affiliated with E*TRADE or any of its affiliates. E*TRADE and its affiliates are not responsible for the content and the content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities.
E*TRADE does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Quotes and other information supplied by independent providers identified on the E*TRADE vendor disclosures page
Statement of Financial Condition | About Asset Protection | Customer/User Agreement | Privacy Statement | Business Continuity Plan | Online Security | Contact Us | About Us | About Our Ads
Securities and futures products and services offered by E*TRADE Securities LLC, Member FINRA/SIPC/NFA. Investment advisory services are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Banking products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. E*TRADE Securities LLC, E*TRADE Capital Management, LLC and E*TRADE Bank are separated but affiliated companies.
System response and account access times may vary due to a variety of factors, including trading volumes, market conditions, system performance, and other factors.
© 2021 E*TRADE Financial Holdings, LLC, a business of Morgan Stanley. All rights reserved.
Sure I get it. We already knew that there's other antivirals out there. Trump was out of the hospital in one day because of it. I'm very LONG on ENZC. The cure for aids is enough for me!! ENZC
It was on Sky News about one hour ago
ENZC
I just heard that the English now have a new anti viral treatment for people sick with covid 19. So we've got competition in the cure field unless it's our own ENZC
A good day Here . Were kickin it today aren't we my friend. C in the Bahamas I'll be the guy with the sunglasses on lol
Enzc
Ènzc
Still buying, still long...Nice reprieve compared to the last few days. Hope we got rid of some of the weaker hands this week. Survival of the fittest in the otc.
I'm thinking that Enzolytics could easily put our ceo on the short list for a NOBLE PEACE PRIZE.
Think about it..
FOR THOSE THAT MISSED THE NEWS YESTERDAY.. ENZC
Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc.
10:19 AM ET 12/1/20 | Dow Jones
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day.
Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. One technology, invented by Harry Zhabilov, the CSO of the Company, is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, the therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy, with 68% of those individuals tested experiencing an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes were also decreased. And the viral load in 80.5% of those tested was below the threshold of detection. This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
The Company is now combining this technology with recently acquired technology for creating fully human anti-monoclonal antibodies for treating HIV. From this technology created by BioClonetics, the Company has a fully human anti-monoclonal antibody that has been tested in 5 international labs where it neutralized over 95% of all strains of the HIV virus against which it was tested. Multiple recombinant forms of this parent antibody are now being produced, and additional neutralizing antibodies are being created to provide combined monoclonal antibody therapies for patients with HIV.
The Company has recently confirmed plans to test its monoclonal antibodies at the University of Strasbourg, France, under the direction of Dr. Christiane Moog, Ph.D., Research Director at INSERM, University of Strasbourg, a leading specialist in conducting the preferred PBMC based in vitro neutralization assays protocol for anti-HIV monoclonal antibodies. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy, under the direction of a further expert in the field, Dr. Gabriella Scarlatti, M.D., Ph.D., Head of Viral Evolution and Transmission Unit at San Raffaele Scientific Institute.
The therapies of Enzolytics' two technologies, that produced by Enzolytics and that created by BioClonetics will be tested in combination and are expected to be synergistic.
Additionally, the Company has identified correlative structure between the HIV virus and the CoronaVirus and, with its capability to produce targeted monoclonal antibodies, is moving forward to produce monoclonal antibodies targeting the CoronaVirus. The Company is extending its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it will be producing both addition monoclonal antibodies against HIV and the against the CoronaVirus.
The Company's addition of Dr. Ronald Moss, MD, to its Medical Advisory Board has provided experienced guidance for its strategies and in its planned testing and validation of its therapeutics in animal and clinical trials.
Harry Zhabilov, CSO of Enzolytics, stated, "The technologies of the combined entities will afford the Company the opportunity to unlock the potential of our HIV-AIDS treatments at a time when the seriousness of the disease is still a major concern given that the current form of treatment for HIV patients is anti-retroviral treatment and where such treatment is only accessible to 40% of the 36 million peoples in the world infected by HIV - leaving 60% of the 36 million infected HIV patients with no treatment."
"The current antiretroviral therapy for HIV/AIDS is not a cure, and the side effects from lifelong use are significant. Also, the yearly average cost of treatment on anti-retroviral is $14,000 to $20,000 per year, and the average lifetime cost is calculated as $379,000. The cost of an anti-HIV therapy we propose would be a fraction of these costs as the treatment would be for a limited time and not require life-long use. Just as monoclonal antibodies were available to President Trump when he contracted the Coronavirus, monoclonal antibodies can be made available to treat HIV patients, and we believe we are on the verge of providing such a therapy", stated Charles Cotropia, CEO of Enzolytics.
About Enzolytics, Inc;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.
Enzolytics' flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. is a Dallas, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for name infectious diseases, including the Coronavirus.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. (f/k/a Eco Petroleum Solutions, Inc. / Immunotech Laboratories, Inc.) from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.
IR Contact:
Enzolytics, Inc.
2000 North Expressway
Plano, TX 75074
Phone: (972) 292-9414
Fax: (972) 292-9414
SOURCE: Enzolytics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/618980/Enzolytics-Inc-Completes-Merger-with-BioClonetics-Immunotherapeutics-Inc
> Dow Jones Newswires
'\
EXACTLY, SHOULD HAVE BEEN STICKIED. ENZC
You might want to try digging deeper next time
Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc.
10:19 AM ET 12/1/20 | Dow Jones
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day.
Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. One technology, invented by Harry Zhabilov, the CSO of the Company, is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, the therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy, with 68% of those individuals tested experiencing an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes were also decreased. And the viral load in 80.5% of those tested was below the threshold of detection. This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for
the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day.
Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. One technology, invented by Harry Zhabilov, the CSO of the Company, is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, the therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy, with 68% of those individuals tested experiencing an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes were also decreased. And the viral load in 80.5% of those tested was below the threshold of detection. This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
The Company is now combining this technology with recently acquired technology for creating fully human anti-monoclonal antibodies for treating HIV. From this technology created by BioClonetics, the Company has a fully human anti-monoclonal antibody that has been tested in 5 international labs where it neutralized over 95% of all strains of the HIV virus against which it was tested. Multiple recombinant forms of this parent antibody are now being produced, and additional neutralizing antibodies are being created to provide combined monoclonal antibody therapies for patients with HIV.
The Company has recently confirmed plans to test its monoclonal antibodies at the University of Strasbourg, France, under the direction of Dr. Christiane Moog, Ph.D., Research Director at INSERM, University of Strasbourg, a leading specialist in conducting the preferred PBMC based in vitro neutralization assays protocol for anti-HIV monoclonal antibodies. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy, under the direction of a further expert in the field, Dr. Gabriella Scarlatti, M.D., Ph.D., Head of Viral Evolution and Transmission Unit at San Raffaele Scientific Institute.
The therapies of Enzolytics' two technologies, that produced by Enzolytics and that created by BioClonetics will be tested in combination and are expected to be synergistic.
Additionally, the Company has identified correlative structure between the HIV virus and the CoronaVirus and, with its capability to produce targeted monoclonal antibodies, is moving forward to produce monoclonal antibodies targeting the CoronaVirus. The Company is extending its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it will be producing both addition monoclonal antibodies against HIV and the against the CoronaVirus.
The Company's addition of Dr. Ronald Moss, MD, to its Medical Advisory Board has provided experienced guidance for its strategies and in its planned testing and validation of its therapeutics in animal and clinical trials.
Harry Zhabilov, CSO of Enzolytics, stated, "The technologies of the combined entities will afford the Company the opportunity to unlock the potential of our HIV-AIDS treatments at a time when the seriousness of the disease is still a major concern given that the current form of treatment for HIV patients is anti-retroviral treatment and where such treatment is only accessible to 40% of the 36 million peoples in the world infected by HIV - leaving 60% of the 36 million infected HIV patients with no treatment."
"The current antiretroviral therapy for HIV/AIDS is not a cure, and the side effects from lifelong use are significant. Also, the yearly average cost of treatment on anti-retroviral is $14,000 to $20,000 per year, and the average lifetime cost is calculated as $379,000. The cost of an anti-HIV therapy we propose would be a fraction of these costs as the treatment would be for a limited time and not require life-long use. Just as monoclonal antibodies were available to President Trump when he contracted the Coronavirus, monoclonal antibodies can be made available to treat HIV patients, and we believe we are on the verge of providing such a therapy", stated Charles Cotropia, CEO of Enzolytics.
About Enzolytics, Inc;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.
Enzolytics' flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. is a Dallas, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for name infectious diseases, including the Coronavirus.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. (f/k/a Eco Petroleum Solutions, Inc. / Immunotech Laboratories, Inc.) from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the
th
It's looking really good this week and for the foreseeable future. Love my ENZC shares
TAKE NO PRISONERS AND SHOW NO MERCY. ENZC = $$$$ THE 300
You and me both my friend... Winner, winner, chicken dinner.. The chicken is for those who sold this ticker. The smarter traders can pretty much look forward to filet mignon forever... Me, I prefer T-bone
This stock has soooo much potential ... Aids, covid and more... what a miracle that we lowly traders in the otc are given the opportunity of a real life saver that can help all of mankind. NOT A Freaking vaccine.. ENZC
Why keep it coming, haven't you had enough yet? There's so much to come and so much money to be made it makes me LMAO with ENZC joy
My pal Juan. Now i know lol(not that i didn't already know) that I'm in the right place.
Juan the potential here is mind boggling. Hell I'm still buying the dips after picking up millions in the trips
ENZC ZOOM ZOOM
What does that even mean? This is a great play to be in, is all I know!!!
ENZC
In f. ing credible... This is hot hot hot.. ENZC
Starting to feel like it could do that this week. Can't beat bio's with a product that's proving its worth ENZC
EXcellent thank you sir. Makin money playing these things. Hope your good as well Juan. ENZC
Not this guy LOL... Hey old friend, good to see ya :) ENZC
If the ask doesn't get slapped we're going to watch it go back down or we're going to see a wall situation . This is the point where slapping is the key to start the chase. I'm going to walk the talk with the rest of my powder. Should be able to get about 2.75 m... vysm
Thanks for all the cheap shares here.... Must be a lot of beer drinkers in vsym
L2 just shifted
For sure time will tell..W@asn't Sannabis part of newc at one time and than split off?
Yeah we need some buying pressure to get out of this $hit
I'm ready to rumble vsym
Good job Getm, Now I'm out of cash. I'll be picking up more again tomorrow
I guess you found some spare change... It's the deal of a life time...
DO
IT
VSYM...LOL saw that.. congrats vsym
Me as well. I thought with all the crying and frustrated sellers we could have been back into tripsville. I believe getting caught up with the filings would or should have got us going up in the right direction. Campos is doing a good job of doing most of what he says this time around. vsym
LOL getm. I know you would. Ive seen you go big a number of times... going to do really well here I'm thinking.. Lots of good stuff going down.... Oh man I want those .0011"s......vsym
anyone here want to help me take out the .0012's? looks like there's about 9m left for now... I can do 3.5m of it vysm